Angela H. Brodie
Affiliations: | Toxicology | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
Molecular Biology, BiochemistryGoogle:
"Angela Brodie"Children
Sign in to add trainee| Tadas S. Vasaitis | grad student | 2007 | University of Maryland Medical School |
| Adam B. Schayowitz | grad student | 2008 | University of Maryland Medical School |
| Rabia A. Gilani | grad student | 2011 | University of Maryland Medical School |
| Amanda J. Schech | grad student | 2012 | University of Maryland Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Schech A, Brodie A, Lewis J, et al. (2020) Targeting Cancer Stem Cells and Metastasis with Epigenetic Modulation and Anti-HER2 Therapy: Phase I/II Trial of Vorinostat in Combination with Lapatinib Computers & Operations Research. 2020: 1-12 |
| Khatri R, Shah P, Guha R, et al. (2018) Retraction: Aromatase Inhibitor-mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer. Molecular Cancer Therapeutics. 17: 2491 |
| Sabnis GJ, Kazi A, Schech A, et al. (2017) Abstract 3604: Effect of a new oral SERD AZD9496 on ER mediated signaling in xenograft model of postmenopausal breast cancer Endocrinology. 77: 3604-3604 |
| Merchenthaler I, Lane M, Sabnis G, et al. (2016) Treatment with an orally bioavailable prodrug of 17β-estradiol alleviates hot flushes without hormonal effects in the periphery. Scientific Reports. 6: 30721 |
| Merino VF, Nguyen N, Jin K, et al. (2016) Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer. Cancer Research |
| Curley MD, Sabnis GJ, Wille L, et al. (2015) Seribantumab, an anti-ERBB3 antibody, delays the onset of resistance and restores sensitivity to letrozole in an estrogen receptor-positive breast cancer model. Molecular Cancer Therapeutics |
| Prokai L, Nguyen V, Szarka S, et al. (2015) The prodrug DHED selectively delivers 17β-estradiol to the brain for treating estrogen-responsive disorders. Science Translational Medicine. 7: 297ra113 |
| Schech AJ, Shah P, Yu S, et al. (2015) Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Research and Treatment |
| Khatri R, Shah P, Guha R, et al. (2015) Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer. Molecular Cancer Therapeutics. 14: 1728-37 |
| Brodie A, Russo J, Pasqualini JR. (2015) Hormones in normal and cancerous breast: basic and clinical applications. Hormone Molecular Biology and Clinical Investigation. 9: 1 |